Clinical Trial Search

Primary: Sensitivity of Scanning a/LCI Probe to Detect Cervical Dysplasia as Measured by Percentage of Correctly Identified Positive Biopsies — 90.3; 100.0 percentage of correct…

Primary: Incidence of Objective Response — 32; 36; 30; 0 Participants — p=0.043

Primary: Pathological Response — 20; 24 participants

Primary: Cumulative Rate of Cervical Intraepithelial Neoplasia (CIN2+) (CIN2, CIN3 or Invasive Cancer) by Week 130 — 24.9; 26.5 Events per 100 persons

Primary: Cumulative Number of Participants Diagnosed by the Community Pathologist With Cervical Intraepithelial Neoplasia Grade 2 or Higher (CIN2+): "Community-based CIN2+"…

Primary: Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia (CIN)(Any Grade), Adenocarcinoma In Situ (AIS) or Cervical Cancer — 0; 1.2 incidence rate per 100…

Primary: Incidence of the Composite Endpoint of Human Papillomavirus (HPV) 16/18-related Cervical Intraepithelial Neoplasia (CIN) 2 or Worse in the Base Study — 0.0; 0.4…

Primary: Feasibility of Intravaginal Use 5-FU and Imiquimod on Alternating Weeks in Women With Biopsy Confirmed High Grade Cervical Squamous Intraepithelial Lesions. — 4; 1…

Primary: Number of Patients With Interferometric Data Acquired From Cervical Epithelium — 3; 41 patients

Primary: Recurrence of Cervical Intraepithelial Neoplasia Among HIV-positive Women — 60; 37 Participants

Primary: Histologic Regression — 40; 34.1 percentage of participants

Primary: Number of Participants With Serious Adverse Events — 0; 0; 0; 0 Participants

Primary: Percentage of Participants With Cervical Intraepithelial Neoplasia III (CIN III) — 10.93; 10.25; 10.84 percentage of participants

Primary: Proportion of Participants With no Evidence of Cervical Dysplasia at 12-months — 0.66 proportion of participants

Primary: Feasibility of Acquiring In-vivo High-Resolution Microendoscopy (HRME) Images of Cervix Prior to Conization

Primary: Cervical HSIL — 46; 39 Participants — p=.29

Primary: Percentage of Participants With a Diagnosis of ≥ CIN2 — 14.0; 0.8 Percentage of participants

Primary: Comparison of Lesion Response Rates of Three Different Doses of HAL PDT and Placebo at 3 Months After Treatment. — 95; 69; 63; 57 percentage of patients

Primary: Safety and Toxicity — 0; 0; 0 Participants

Primary: Prevalence of Abnormal Cervical Cytology — 12 Participants

Primary: Acceptability of Self-Collection Paired With Mobile Mammography — 33 Participants

Primary: Number of Participants With Recurrence of Dysplasia — 5; 8 Participants

Primary: Concordance of Pap Test Results Between Self- and Physician-collected Pap Tests — 8; 89; 2; 3 Participants

Primary: Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 125; 2; 122; 3 Participants

Primary: Number of Participants Who Scheduled or Completed Cervical Cancer Screening — 28; 21 Participants

Primary: Proportion of Participants With Residual CIN2+ — 18; 29; 25 Participants

Primary: Mean Depth of Necrosis Achieved With the LMIC-adapted CryoPen and the Thermocoagulator Compared to Mean Depth of Necrosis Achieved With CO2-based Cryotherapy — 6.0; 5.6…

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 1; 0 Participants

Primary: Proportion of Patients With Regression of Perianal High-grade Squamous Intraepithelial Lesions (HSIL) — 0.515 proportion of participants

Primary: Number of Participants With Related Serious Adverse Events — 0; 0; 0; 0 Participants